Trial Profile
A Phase I, Dose-escalation Trial of Rituxan and Bendamustine in Combination With Bruton's Tyrosine Kinase Inhibitor, PCI-32765, in Patients With Relapsed Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Indolent Non-Hodgkin's Lymphoma.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 15 Feb 2024
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Ibrutinib (Primary) ; Rituximab (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- 09 Feb 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 01 Nov 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 27 Jun 2022 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.